Ilumya

The U.S. Food and Drug Administration (FDA) has approved Ilumya (tildrakizumab-asmn), an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ilumya is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

It is not known if this medicine is safe and effective in children under 18 years of age.

Before receiving Ilumya, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section Important information.
• have an infection that does not go away or that keeps coming back
• have TB or have been in close contact with someone with TB
• recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with Ilumya.
• are pregnant or plan to become pregnant. It is not known if Ilumya can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if Ilumya passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

• Ilumya should only be given to you by a healthcare provider.
• Ilumya is given as an injection under your skin (subcutaneous injection) in areas of your body such as your thighs, stomach area (abdomen), or upper arm.
• If you miss a follow-up appointment and do not receive your dose, schedule another appointment as soon as possible.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

General

Tildrakizumab-asmn is available in the following dosage form(s) and strength(s):

Injection: 100 mg/mL solution in a single-dose prefilled syringe. 1

Dosage

It is essential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

• Administer by subcutaneous injection.1

• Recommended dose is 100 mg at Weeks 0, 4, and every twelve weeks thereafter.1

• Tell all of your health care providers that you take Ilumya (tildrakizumab-asmn). This includes your doctors, nurses, pharmacists, and dentists.
• Make sure you are up to date with all your vaccines before treatment with Ilumya (tildrakizumab-asmn).
• Talk with your doctor before getting any vaccines. Use with Ilumya (tildrakizumab-asmn) may either raise the chance of an infection or make the vaccine not work as well.
• You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.
• TB (tuberculosis) has been seen in patients started on Ilumya (tildrakizumab-asmn). These patients were exposed to TB in the past, but never got the infection. You will be tested to see if you have been exposed to TB before starting Ilumya (tildrakizumab-asmn).
• Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using Ilumya (tildrakizumab-asmn) while you are pregnant.
• Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.

• If you need to store Ilumya (tildrakizumab-asmn) at home, talk with your doctor, nurse, or pharmacist about how to store it.